Cite
MLA Citation
Kenneth Cusi et al.. “Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study.” Lancet gastroenterology and hepatology, vol. 6, 2021, pp. 889–902. http://access.bl.uk/ark:/81055/vdc_100144510712.0x000005